PUIGHERMANAL, Emma; LUNA-SÁNCHEZ, Marta; GELLA, Alejandro; VAN DER WALT, Gunter; URPI, Andrea; ROYO, María; TENA-MORRAJA, Paula; APPIAH, Isabella; DE DONATO, Maria Helena; MENARDY, Fabien; BIANCHI, Patrizia; ESTEVE-CODINA, Anna; RODRÍGUEZ-PASCAU, Laura; VERGARA, Cristina; GÓMEZ-PALLARÈS, Mercè; MARSICANO, Giovanni; BELLOCCHIO, Luigi; MARTINELL, Marc; SANZ, Elisenda; JURADO, Sandra; SORIANO, Francesc Xavier; PIZCUETA, Pilar; QUINTANA, Albert

doi:10.1038/s41467-024-51884-8

Idioma

Article de revue

Este ítem está publicado en

Nature Communications. 2024-09-04, vol. 15, n° 1

Resumen en inglés

Mutations in mitochondrial energy-producing genes lead to a heterogeneous group of untreatable disorders known as primary mitochondrial diseases (MD). Leigh syndrome (LS) is the most common pediatric MD and is characterized by progressive neuromuscular affectation and premature death. Here, we show that daily cannabidiol (CBD) administration significantly extends lifespan and ameliorates pathology in two LS mouse models, and improves cellular function in fibroblasts from LS patients. CBD delays motor decline and neurodegenerative signs, improves social deficits and breathing abnormalities, decreases thermally induced seizures, and improves neuropathology in affected brain regions. Mechanistically, we identify peroxisome proliferator-activated receptor gamma (PPARγ) as a key nuclear receptor mediating CBD’s beneficial effects, while also providing proof of dysregulated PPARγ expression and activity as a common feature in both mouse neurons and fibroblasts from LS patients. Taken together, our results provide the first evidence for CBD as a potential treatment for LS. © The Author(s) 2024.< Leer menos

URI

https://oskar-bordeaux.fr/handle/20.500.12278/206656

DOI

http://dx.doi.org/10.1038/s41467-024-51884-8

Proyecto europeo

Elucidating Neuronal Susceptibility to Mitochondrial Disease

Centros de investigación

Neurocentre Magendie - U1215

Ver/Abrir

Metadatos

Compartir este ítem

Licencia de uso del documento

Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models

Idioma

Este ítem está publicado en

Resumen en inglés

URI

DOI

Proyecto europeo

Centros de investigación